EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitScoping ReviewOpen Access · CC BY 4.0

Management and Clinical Outcomes of Scleredema Diabeticorum: A Scoping Review

Weeratian Tawanwongsri iD, Chime Eden iD

Diseases · 17.10.2025 · 13 (10) · 346

DOI: 10.3390/diseases13100346 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diseases, online erschienen am 17.10.2025. Verfasst von Weeratian Tawanwongsri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The objective of this scoping review was to systematically map the available evidence for the management of scleredema diabeticorum (SD) to summarize the documented clinical outcomes with the aim to inform clinical practice and identify research gaps.

Methods

We conducted a scoping review identifying studies published in English from January 2005 to July 2025 through a comprehensive search of Scopus, MEDLINE, and the Cochrane Library. Eligible studies included randomized controlled trials, observational studies, case series, and case reports on treatment interventions and clinical outcomes. Two reviewers independently screened records, extracted data, and narratively and descriptively synthesized data.

Results

Forty-five studies met the inclusion criteria: 39 single-patient case reports, five case series, and one multicenter observational study. The most common interventions were PUVA (8 studies, 14 patients; 12/14 improved, 85.7%), methotrexate (8 studies, 22 patients; 8/22 improved, 36.4%), and improved glycemic control (9 studies, 12 patients; mixed responses). Across small case reports/series, PUVA, UVA-1, and IVIG were most frequently reported as beneficial. Methotrexate monotherapy showed low and inconsistent effectiveness, with higher responses when combined with other agents. Other reported therapies included colchicine, electron-beam radiation, tranilast, and topical hyaluronidase.

Conclusions

PUVA, UVA-1, and IVIG may offer benefit, while methotrexate alone is often ineffective. Evidence is predominantly from case reports and small series, which makes it difficult to generalize. Multicenter trials with standardized protocols are needed to develop evidence-based treatment recommendations.

Schlagwörter

Stichwörter der Autor:innen

diabetes mellitusdisease managementglycemic controlscleredema adultorumtreatment outcome

Autor:innen und Institutionen

  • Division of Dermatology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand.
  • Division of Dermatology, Jigme Dorji Wangchuck National Referral Hospital (JDWNRH), Thimphu 11001, Bhutan.

ORCID-Profile: Weeratian Tawanwongsri, Chime Eden

Zitieren

APA

Tawanwongsri, W., & Eden, C. (2025). Management and Clinical Outcomes of Scleredema Diabeticorum: A Scoping Review. Diseases, 13(10), 346. https://doi.org/10.3390/diseases13100346

Vancouver

Tawanwongsri W, Eden C. Management and Clinical Outcomes of Scleredema Diabeticorum: A Scoping Review. Diseases. 2025;13(10):346. doi:10.3390/diseases13100346

BibTeX
@article{Tawanwongsri2025,
  author = {Tawanwongsri, Weeratian and Eden, Chime},
  title = {Management and Clinical Outcomes of Scleredema Diabeticorum: A Scoping Review},
  journal = {Diseases},
  year = {2025},
  volume = {13},
  number = {10},
  pages = {346},
  doi = {10.3390/diseases13100346}
}
Kostenlos starten →